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LETTERS to the EDITOR
Restricting benzodiazepine prescribing
SIR,-Mrs Brahams (Dec 1, p 1372) describes the regulation
adopted by New York State to reduce benzodiazepine prescribing.
She concludes that the evidence published by the state about the
favourable effects of this regulation is "overwhelming". We have
reservations about this evidence but our main point is that
regulations that may affect the availability of therapeutic drugs
should be adopted only after careful evaluation of possible benefits
and risks and, before they are adopted, provision should be made for
equally careful assessment of effects on legitimate use as well as on
possible misuse or abuse.’ 2
The New York State Department of Health (NYSDH) assumes
that benzodiazepine prescribing is excessive and that a reduction
will reduce misuse and abuse but will not adversely affect public
health. These assumptions have not really been tested, much less
substantiated.’ Who is supposed to benefit from the regulation?
According to Brahams the position of the NYSDH is that the
primary objectives were "to reduce the diversion of
benzodiazepines into illicit use and to reduce inappropriate
prescribing". A further objective is that the state is achieving great
savings as a result of the reduction in prescriptions the state has to
reimburse under Medicaid and other programmes. The primary
objectives are desirable. However, Dr Blum notes (Dec 22/29,
p 1586) the NYSDH data cited as evidence that the regulation is
achieving these objectives refer to events that long predated the
regulation. Indeed, it is not at all clear that these objectives can be
realised by this type of regulation. Blum makes the point that the
savings claimed may easily be offset by additional costs necessitated
by the regulation, many of which must be borne chiefly by patients.
More importantly, these objectives neglect the welfare of patients
with conditions for which benzodiazepines are effective. As we
concluded,3 and as Blum also points out, these patients vastly
outnumber those who intentionally or unintentionally misuse these
drugs. Numbers apart, we would argue that it is not acceptable to
risk denying reief to one patient on the grounds that one might
thereby prevent drug abuse in another person.
Brahams reports that the objectives have been received "without
interrupting legitimate use" but neither the NYSDH publication
she cites nor any other evidence we are aware of supports this
generalisation. Moreover, a chilling effect of the regulation is to risk
exacerbating the undertreatment of anxiety and insomnia: most
people with these disorders go without treatment,’5 and there is
evidence linking anxiety disorders with increased risks of
depression,b alcoholism,7 suicide,8 and death due to unnatural
causes. 9
"Allegations that doctors would simply prescribe alternatives has
also proved groundless", Brahams states. On the contrary, market
research data show that, in the nine months after the regulation took
effect, prescriptions for possible alternatives increased strikingly, in
contrast to trends in the rest of the United States. For example,
prescriptions for meprobamate increased by 17% (as opposed to a
10% decline in the rest of the country), prescriptions for chloral
hydrate rose by 158% (4% increase), and barbiturate prescriptions
went up by 41% (11% decline)." Pharmacological and
epidemiological evidence on the relative toxicity of sedative-
hypnotics makes it clear that these trends may represent a
substantial backward step for the public health in New York State.
Brahams also claims "a 27-53% decrease in benzodiazepine-
prescriptions and a startling reduction in overdose emergency
admissions [involving benzodiazepines]". The "startling
reduction" in emergency admissions was 39% or so (ie, probably
corresponding to the overall decrease in prescriptions). Most
emergency room episodes in which benzodiazepines are involved
also involve other drugs, which are far more likely to be responsible
for the toxic effects The statistics cited by Brahams and by the
NYSDH show that the incidence of emergency room episodes in
which benzodiazepines are involved reflects not the toxicity of these
drugs, but simply the prevalence of their use, and varies in direct
relation to their availability.
The regulation of therapeutic drugs has been distinguished by a
long history of opinion and bias more than of dispassionate
evaluation of evidence. The New York State regulation continues
this unfortunate tradition and is more likely to jeopardise than
protect the public health. Policies affecting the availability of
therapeutic drugs should be subject to the same standards of
rational evaluation as the drugs themselves, and should be allowed
only if they can be shown likely to prove safe and effective.
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Analysis of treatment outcome in problem
drinking
SIR,-In their comparison of specialist and general practitioner
(GP) treatment of problem drinking Dr Drummond and colleagues
(Oct 13, p 915) ask if their failure to find a significant difference in
outcome could have been due to the small sample size (n1 =18,
n2 = 19). They note that such a type I I error cannot be excluded but
that they did find a significant reduction within the two groups, in
the absence of a significant difference between groups.
What size of difference between groups did their study have the
power to detect? For their initial sample size (n, = n, = 20) and with
a-=005 and power at 80%, the study could detect differences
between means of just over 09 SD.1-3 In clinical research in general
and certainly for treatment outcome in problem drinking this would
be a large difference. In Drummond’s study a difference of 0-9 SD
would mean, for daily units of alcohol reportedly consumed,
decreases of 11 units in one group and 4 units in the other. The
study is even more inadequate for comparing proportions between
the two groups. Only differences as large or larger than 5% vs 39%,
20% vs 63%, or 50% vs 89%Z could have been detected with a
power of 80%.’
